InflaRx (IFRX) shares sank 60% after the company said Wednesday it plans to discontinue development of vilobelimab in pyoderma gangrenosum, a rare and inflammatory skin disease.
More than 5.48 million shares traded intraday, compared with a daily average of about 301,000.
Cemtrex (CETX) said it priced a firm commitment underwritten public offering of 1.25 million shares at $1.00 apiece.
Shares slumped 46%, with intraday trading volume of over 2.56 million against a daily average of about 299,000.
Exodus Movement (EXOD) filed a registration statement late Tuesday for the sale of up to $1 billion of securities, including class A stock and debt, from time to time.
Shares dropped 21% as intraday trading volume rose to more than 220,000 from a daily average of roughly 96,000.
Price: 0.73, Change: -1.09, Percent Change: -59.89
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。